Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 806.00K | 2.25M | 3.56M | 2.30M | 1.09M |
| Total Depreciation and Amortization | 8.19M | 7.18M | 6.19M | 5.88M | 5.77M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.72M | 8.77M | 10.03M | 8.24M | 8.82M |
| Change in Net Operating Assets | 4.04M | 5.84M | 3.58M | 5.78M | 7.01M |
| Cash from Operations | 19.76M | 24.03M | 23.37M | 22.20M | 22.69M |
| Capital Expenditure | -276.00K | -183.00K | -132.00K | -75.00K | -54.00K |
| Sale of Property, Plant, and Equipment | 653.00K | -- | -- | -- | -- |
| Cash Acquisitions | -3.20M | -3.28M | -1.59M | -2.96M | -3.09M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.04M | -2.54M | -2.76M | -2.72M | -216.00K |
| Cash from Investing | -7.87M | -6.00M | -4.48M | -5.75M | -3.36M |
| Total Debt Issued | -- | -- | 17.58M | 17.58M | 17.58M |
| Total Debt Repaid | -26.43M | -14.24M | -13.57M | -49.59M | -47.31M |
| Issuance of Common Stock | 19.30M | 19.30M | -- | 25.19M | 25.19M |
| Repurchase of Common Stock | -- | -- | -17.58M | -17.58M | -17.58M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.87M | -4.27M | -4.76M | -4.62M | -4.45M |
| Cash from Financing | -11.00M | 796.00K | -18.33M | -29.03M | -26.58M |
| Foreign Exchange rate Adjustments | -17.00K | -111.00K | -331.00K | 51.00K | -87.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 878.00K | 18.72M | 228.00K | -12.53M | -7.33M |